Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial

A Meisel; S von Felten; D R Vogt; H Liewen; Ronald de Wit; J De Bono; O Sartor; F Stenner-Liewen

doi:10.1016/j.ejca.2015.12.009

Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial

A Meisel, S von Felten, D R Vogt, H Liewen, Ronald de Wit, J De Bono, O Sartor, F Stenner-Liewen

Medical Oncology

Research output: Contribution to journal › Article › Academic › peer-review

65 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	93-100
Number of pages	8
Journal	European Journal of Cancer
Volume	56
DOIs	https://doi.org/10.1016/j.ejca.2015.12.009
Publication status	Published - 2016

Research programs

EMC MM-03-86-08

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ejca.2015.12.009

Cite this

Meisel, A., von Felten, S., Vogt, D. R., Liewen, H., de Wit, R., De Bono, J., Sartor, O., & Stenner-Liewen, F. (2016). Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial. European Journal of Cancer, 56, 93-100. https://doi.org/10.1016/j.ejca.2015.12.009

@article{1ae05cb0e50640d9b41b84f9ba3d0543,

title = "Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial",

author = "A Meisel and {von Felten}, S and Vogt, {D R} and H Liewen and {de Wit}, Ronald and {De Bono}, J and O Sartor and F Stenner-Liewen",

year = "2016",

doi = "10.1016/j.ejca.2015.12.009",

language = "Undefined/Unknown",

volume = "56",

pages = "93--100",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd.",

}

Meisel, A, von Felten, S, Vogt, DR, Liewen, H, de Wit, R, De Bono, J, Sartor, O & Stenner-Liewen, F 2016, 'Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial', European Journal of Cancer, vol. 56, pp. 93-100. https://doi.org/10.1016/j.ejca.2015.12.009

Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial. / Meisel, A; von Felten, S; Vogt, D R et al.
In: European Journal of Cancer, Vol. 56, 2016, p. 93-100.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial

AU - Meisel, A

AU - von Felten, S

AU - Vogt, D R

AU - Liewen, H

AU - de Wit, Ronald

AU - De Bono, J

AU - Sartor, O

AU - Stenner-Liewen, F

PY - 2016

Y1 - 2016

U2 - 10.1016/j.ejca.2015.12.009

DO - 10.1016/j.ejca.2015.12.009

M3 - Article

C2 - 26829012

SN - 0959-8049

VL - 56

SP - 93

EP - 100

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -